Publications by authors named "Thomas Son"

Claim this Profile
P
Preclinical development of MGC028, an ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid cancers.
Juniper A Scribner, Jennifer G Brown, Thomas Son, Linda Jin, Carroll McKenzie

Mol Cancer Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dual insect symbiont and plant pathogen improves insect host fitness under arginine limitation.
Younghwan Kwak, Jacob A Argandona, Sen Miao, Thomas J Son, Allison K Hansen

mBio· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors.
Juniper A Scribner, Stuart W Hicks, Kerstin W Sinkevicius, Nicholas C Yoder, Gundo Diedrich, Thomas Son

Mol Cancer Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Juniper A Scribner, Jennifer G Brown, Thomas Son, Michael Chiechi, Pam Li

Mol Cancer Ther· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.
Stefania Risso Bradley, Jelveh Lameh, Linda Ohrmund, Thomas Son, Abhishek Bajpai

Neuropharmacology· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator.
Fabrice Piu, Luis R Gardell, Thomas Son, Nathalie Schlienger, Birgitte W Lund, Roger Olsson

J Steroid Biochem Mol Biol· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
Kimberly E Vanover, David M Weiner, Malath Makhay, Isaac Veinbergs, Luis R Gardell, Carl Magnus Andersson, Thomas Y Son

J Pharmacol Exp Ther· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist.
Kimberly E Vanover, Scott C Harvey, Thomas Son, Stefania Risso Bradley, Henriette Kold, Carl Magnus Andersson

J Pharmacol Exp Ther· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis